mirage

IDegLira is efficacious across baseline HbA1c categories in subjects with Type 2 diabetes uncontrolled on sulphonylurea, glucagon-like peptide-1 receptor agonist or insulin glargine U100: analyses from completed phase 3b trials

Repositorio ABACUS/Manakin

Mostrar el registro sencillo del ítem

dc.contributor.author Viljoen, A.
dc.contributor.author Sorli, Ch.
dc.contributor.author Harris, S.
dc.contributor.author Jódar Gimeno, Esteban
dc.contributor.author Lingvay, Ildiko
dc.contributor.author Chandarana, K.
dc.contributor.author Langer, J.
dc.contributor.author Jaeckel, E.
dc.date.accessioned 2018-04-16T07:35:16Z
dc.date.available 2018-04-16T07:35:16Z
dc.date.issued 2017
dc.identifier.citation Viljoen, A., Sorli, Ch., Harris, S., Jódar, E. Lingvay, I., Chandarana, K., …& Jaeckel, E. (2017). IDegLira is efficacious across baseline HbA1c categories in subjects with Type 2 diabetes uncontrolled on sulphonylurea, glucagon-like peptide-1 receptor agonist or insulin glargine U100: analyses from completed phase 3b trials. Trabajo presentado en la Diabetes UK Professional Conference, Manchester. Recuperado de http://dx.doi.org/10.1111/dme.37_13304 spa
dc.identifier.uri http://hdl.handle.net/11268/7223
dc.description.abstract Aims: Previous analyses of phase 3a trials (DUAL I extension;DUAL II) showed IDegLira (insulin degludec/liraglutide combina-tion) is efficacious irrespective of baseline HbA1c. This analysisaimed to confirm this observation in additional populations withType 2 diabetes uncontrolled on (i) a glucagon-like peptide-1receptor agonist (GLP-1RA) (DUAL III: IDegLira vs unchangedGLP-1RA), (ii) sulphonylurea metformin (DUAL IV: IDegLiravs placebo) or (iii) insulin glargine (IGlar U100) (DUAL V:IDegLira vs continued IGlar U100 titration). Methods: DUAL III–V were 26 week, randomised trials. IDe-gLira starting dose was 10 dose steps (1 dose step = 1 unit IDeg +0.036mg Lira) in DUAL IV and 16 dose steps in DUAL III and V;maximum IDegLira dose: 50 dose steps. This post hoc analysisgrouped subjects by baseline HbA1c; ≤7.5, > 7.5–≤8.5and > 8.5%. Results: In all trials a higher baseline HbA1c resulted in greaterHbA1c reductions. The change in HbA1c was significantly greater(p < 0.01) with IDegLira vs comparator in all baseline HbA1cgroups with a similar estimated treatment difference (baselineHbA1c ≤7.5, > 7.5–≤8.5 and > 8.5%: -0.74, -1.13, -1.18; -0.91, -1.00, -1.36; -0.48, -0.55, -0.68 for DUAL III, IV and V,respectively). In all trials for all baseline HbA1c groups, IDegLiradecreased mean HbA1c to < 7% at end of trial. In DUAL V, theonly trial to include patients with HbA1c > 9% (median 9.5%),HbA1c was reduced to 6.9% with IDegLira vs 7.8% with IGlarU100. Conclusions: Significant HbA1c reductions occur with IDegLiraregardless of baseline HbA1c group or study population. spa
dc.description.sponsorship SIN FINANCIACIÓN spa
dc.language.iso eng spa
dc.title IDegLira is efficacious across baseline HbA1c categories in subjects with Type 2 diabetes uncontrolled on sulphonylurea, glucagon-like peptide-1 receptor agonist or insulin glargine U100: analyses from completed phase 3b trials spa
dc.type conferenceObject spa
dc.description.impact No data (2017) spa
dc.identifier.doi 10.1111/dme.37_13304
dc.rights.accessRights closedAccess spa
dc.subject.uem Diabetes tipo 2 spa
dc.subject.uem Medicamentos spa
dc.subject.unesco Sistema endocrino spa
dc.subject.unesco Enfermedad spa
dc.description.filiation UEM spa
dc.peerreviewed Si spa


Ficheros en el ítem

Ficheros Tamaño Formato Ver

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem